Effect of long-term belimumab treatment on b cells in systemic lupus erythematosus: Extension of a phase II, double-blind, placebo-controlled, dose-ranging study

Annett M. Jacobi; Weiqing Huang; Tao Wang; William Freimuth; Inaki Sanz; Richard Furie; Meggan Mackay; Cynthia Aranow; Betty Diamond; Anne Davidson

doi:10.1002/art.27189

Effect of long-term belimumab treatment on b cells in systemic lupus erythematosus: Extension of a phase II, double-blind, placebo-controlled, dose-ranging study

Arthritis & Rheumatism ◽

10.1002/art.27189 ◽

2010 ◽

Vol 62 (1) ◽

pp. 201-210 ◽

Cited By ~ 130

Author(s):

Annett M. Jacobi ◽

Weiqing Huang ◽

Tao Wang ◽

William Freimuth ◽

Inaki Sanz ◽

...

Keyword(s):

Systemic Lupus Erythematosus ◽

B Cells ◽

Phase Ii ◽

Lupus Erythematosus ◽

Systemic Lupus ◽

Double Blind ◽

Double Blind Placebo ◽

Dose Ranging

Download Full-text

A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus

Arthritis & Rheumatism ◽

10.1002/art.24699 ◽

2009 ◽

Vol 61 (9) ◽

pp. 1168-1178 ◽

Cited By ~ 368

Author(s):

Daniel J. Wallace ◽

William Stohl ◽

Richard A. Furie ◽

Jeffrey R. Lisse ◽

James D. McKay ◽

...

Keyword(s):

Systemic Lupus Erythematosus ◽

Phase Ii ◽

Lupus Erythematosus ◽

Active Systemic Lupus Erythematosus ◽

Systemic Lupus ◽

Double Blind ◽

Double Blind Placebo ◽

Dose Ranging

Download Full-text

Faculty Opinions recommendation of Pharmacokinetics, tolerability, and preliminary efficacy of paquinimod (ABR-215757), a new quinoline-3-carboxamide derivative: studies in lupus-prone mice and a multicenter, randomized, double-blind, placebo-controlled, repeat-dose, dose-ranging study in patients with systemic lupus erythematosus.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.714897805.790252957 ◽

2012 ◽

Author(s):

Tsutomu Takeuchi ◽

Hideto Kameda

Keyword(s):

Systemic Lupus Erythematosus ◽

Lupus Erythematosus ◽

Repeat Dose ◽

Systemic Lupus ◽

Double Blind ◽

Double Blind Placebo ◽

Dose Ranging

Download Full-text

Maintenance of Efficacy and Safety of Ustekinumab Through One Year in a Phase II Multicenter, Prospective, Randomized, Double‐Blind, Placebo‐Controlled Crossover Trial of Patients With Active Systemic Lupus Erythematosus

Arthritis & Rheumatology ◽

10.1002/art.41179 ◽

2020 ◽

Vol 72 (5) ◽

pp. 761-768 ◽

Cited By ~ 10

Author(s):

Ronald F. Vollenhoven ◽

Bevra H. Hahn ◽

George C. Tsokos ◽

Peter Lipsky ◽

Kaiyin Fei ◽

...

Keyword(s):

Systemic Lupus Erythematosus ◽

Phase Ii ◽

Lupus Erythematosus ◽

Crossover Trial ◽

Active Systemic Lupus Erythematosus ◽

Efficacy And Safety ◽

Systemic Lupus ◽

Double Blind ◽

Double Blind Placebo ◽

One Year

Download Full-text

Faculty Opinions recommendation of Pharmacokinetics, tolerability, and preliminary efficacy of paquinimod (ABR-215757), a new quinoline-3-carboxamide derivative: studies in lupus-prone mice and a multicenter, randomized, double-blind, placebo-controlled, repeat-dose, dose-ranging study in patients with systemic lupus erythematosus.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.714897805.791652962 ◽

2012 ◽

Author(s):

Ann Reed ◽

Vaidehi Chowdhary

Keyword(s):

Systemic Lupus Erythematosus ◽

Lupus Erythematosus ◽

Repeat Dose ◽

Systemic Lupus ◽

Double Blind ◽

Double Blind Placebo ◽

Dose Ranging

Download Full-text

Faculty Opinions recommendation of Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.725732407.793547378 ◽

2018 ◽

Author(s):

Maria Laura Bertolaccini

Keyword(s):

Systemic Lupus Erythematosus ◽

Monoclonal Antibody ◽

Lupus Erythematosus ◽

Phase Iii ◽

Controlled Study ◽

Efficacy And Safety ◽

Systemic Lupus ◽

Double Blind ◽

Double Blind Placebo ◽

B Cell Activating Factor

Download Full-text

Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double-Blind, Placebo-Controlled Trials

Arthritis & Rheumatology ◽

10.1002/art.39856 ◽

2017 ◽

Vol 69 (2) ◽

pp. 362-375 ◽

Cited By ~ 78

Author(s):

Megan E. B. Clowse ◽

Daniel J. Wallace ◽

Richard A. Furie ◽

Michelle A. Petri ◽

Marilyn C. Pike ◽

...

Keyword(s):

Systemic Lupus Erythematosus ◽

Lupus Erythematosus ◽

Active Systemic Lupus Erythematosus ◽

Phase Iii ◽

Controlled Trials ◽

Efficacy And Safety ◽

Systemic Lupus ◽

Two Phase ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Omega-3 in SLE: a double-blind, placebo-controlled randomized clinical trial of endothelial dysfunction and disease activity in systemic lupus erythematosus

Rheumatology International ◽

10.1007/s00296-013-2811-3 ◽

2013 ◽

Vol 33 (11) ◽

pp. 2789-2796 ◽

Cited By ~ 28

Author(s):

Kayode J. Bello ◽

Hong Fang ◽

Parastoo Fazeli ◽

Waleed Bolad ◽

Mary Corretti ◽

...

Keyword(s):

Systemic Lupus Erythematosus ◽

Clinical Trial ◽

Endothelial Dysfunction ◽

Disease Activity ◽

Randomized Clinical Trial ◽

Lupus Erythematosus ◽

Omega 3 ◽

Systemic Lupus ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

OP0019 Baricitinib in systemic lupus erythematosus (SLE): results from a phase 2, randomised, double-blind, placebo-controlled study

10.1136/annrheumdis-2018-eular.1918 ◽

2018 ◽

Cited By ~ 1

Author(s):

D.J. Wallace ◽

R.A. Furie ◽

Y. Tanaka ◽

K.C. Kalunian ◽

M. Mosca ◽

...

Keyword(s):

Systemic Lupus Erythematosus ◽

Lupus Erythematosus ◽

Controlled Study ◽

Phase 2 ◽

Systemic Lupus ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

A double blind, placebo controlled trial of intravenous methylprednisolone in systemic lupus erythematosus.

Annals of the Rheumatic Diseases ◽

10.1136/ard.47.6.496 ◽

1988 ◽

Vol 47 (6) ◽

pp. 496-502 ◽

Cited By ~ 25

Author(s):

C G Mackworth-Young ◽

J David ◽

S H Morgan ◽

G R Hughes

Keyword(s):

Systemic Lupus Erythematosus ◽

Lupus Erythematosus ◽

Controlled Trial ◽

Systemic Lupus ◽

Intravenous Methylprednisolone ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: Results of a multicenter, phase ib, double-blind, placebo-controlled, dose-escalating trial

Arthritis & Rheumatism ◽

10.1002/art.23047 ◽

2007 ◽

Vol 56 (12) ◽

pp. 4142-4150 ◽

Cited By ~ 219

Author(s):

Maria Dall'Era ◽

Eliza Chakravarty ◽

Daniel Wallace ◽

Mark Genovese ◽

Michael Weisman ◽

...

Keyword(s):

Systemic Lupus Erythematosus ◽

Lupus Erythematosus ◽

B Lymphocyte ◽

Systemic Lupus ◽

Double Blind ◽

Double Blind Placebo ◽

Phase Ib ◽

Multicenter Phase ◽

Immunoglobulin Levels ◽

Dose Escalating

Download Full-text